Medical Professionals

At Verastem Oncology, we aim to engage and partner with the medical and scientific community to advance research and develop and deliver new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway–driven cancers. 

RAS/MAPK pathway–driven cancers are often aggressive, and mutations on the pathway—found in nearly one-third of all human cancers—are associated with poor outcomes that leave patients with few treatment choices.^1,2 Despite advances in RAS/MAPK–targeting therapies, resistance remains a challenge, and many pathway mutations still lack specific therapies.² At Verastem Oncology, we are here to change that. 

We believe the path to improving how RAS/MAPK pathway–driven cancers are treated requires developing innovative treatments that inhibit mutations in the pathway while also overcoming resistance mechanisms. Our pipeline is focused on novel small molecule inhibitors that interfere with critical signaling pathways that promote cancer cell survival and tumor growth in cancer. Our portfolio includes inhibitors of RAF/MEK, FAK, and KRAS G12D. 

Resources 

Request Medical Information 

Verastem is dedicated to providing healthcare professionals (HCPs) with accurate and timely product information. If you need medical information about our products or wish to report an adverse event or product complaint, please contact Verastem Medical Information Services at: 

Phone: 1-833-633-8786
Email: medinfo@verastem.com 
Fax: 781-707-0499

We are here to assist you. 

Medical Education Grants and Sponsorships 

Medical Education Grants 

In alignment with corporate areas of interest, Verastem will consider Independent Medical Education (IME) programs for HCPs that are designed and implemented independent of any Verastem influence or input (as defined by standards such as the Accreditation Council for Continuing Medical Education (ACCME) guidelines, the FDA’s Guidance on Industry Supported Scientific and Educational Activities, and country/region–specific standards and guidelines (as applicable)). 

Verastem is currently accepting applications from educational providers that are accredited to provide continuing education (i.e., CME or CE) by a national accrediting body, such as ACCME, Committee on Accreditation of Continuing Medical Education (CACME), European Accreditation Council for Continuing Medical Education (EACCME), American Nurses Credentialing Center (ANCC), Accreditation Council for Pharmacy Education (ACPE), or other such accreditors, including country/region–specific accreditors (as applicable). 

For questions about our medical education grants or to submit a grants request, please download, complete and submit the form below via email to medgrants@verastem.com.  

Who May Apply:  

• Accredited providers  
• Patient advocacy organizations  
• Medical associations

Areas of interest:  

• Rare tumors in ovarian cancer education 
  • LGSOC disease state
• KRAS-driven tumors education
  • Including pancreatic and lung 
• New advances or treatment in ovarian cancer
  • Sub-population of LGSOC
• Molecular testing in ovarian cancer
  • Sub-population of LGSOC

Scientific Sponsorships  

Verastem will consider support in the form of financial contributions to eligible organizations for scientific initiatives and events, programs, and projects in which Verastem is involved or receives tangible benefit. 

These events may be medical/scientific in nature. Examples include but are not limited to event sponsorships, corporate memberships, advertising opportunities, exhibit booths, awards, congress support, health awareness campaigns, roundtables, forums, and satellite symposiums. 

Submission of a request for support does not imply or guarantee approval. Requestors will be notified by Verastem of the decision to either decline or grant support, along with next steps. For questions about our scientific sponsorships or to submit a sponsorship request, please download, complete and submit the form below via email to medgrants@verastem.com. 

Investigator Sponsored Trials (IST) 

We believe in the power of collaboration to help us push forward with new and promising cancer treatments. Our Verastem Oncology Investigator Sponsored Trial (IST) program strives to advance medical and scientific knowledge for our product candidates and disease states of interest. We welcome partnerships with researchers and sponsoring institutions that build on this mission. 

Investigator Sponsored Trial Form 

For additional details regarding our IST program or to submit a research request, please download, complete and submit the form below via email to verastem-IST@verastem.com. 

Research Collaborations 

Verastem Oncology also accepts proposals for preclinical research collaborations. For more information, please reach out to us at research@verastem.com. 

Expanded Access  

Verastem Oncology is a biopharmaceutical company committed to advancing new medicines for patients battling cancer, and we are also working to bring these medicines to patients as quickly and safely as possible. As both of our investigational agents, avutometinib and defactinib, are in clinical trials to evaluate their efficacy and safety, we are not currently providing access to these therapies outside of clinical trials. At this time, we believe participation in a clinical trial is the optimal way to access these investigational therapies to enable thorough evaluation and support regulatory approvals. Individuals participating in our clinical trials are provided with the treatment being tested. The purpose of these trials is to determine whether the treatment is safe and effective. We submit a full complement of evidence from trials and other data to regulatory authorities, who make the final decision to approve the treatment or not. Until the regulatory authority has made this decision, the treatment remains experimental and not yet available to patients. 

If you have questions about our programs or eligibility for our clinical trials, please contact us at clinicaltrials@verastem.com. A list of current clinical trials can be found at clinicaltrials.gov.